Dynamic Technology Lab Private Ltd Lowers Stake in Geron Co. (NASDAQ:GERN)

Dynamic Technology Lab Private Ltd cut its holdings in shares of Geron Co. (NASDAQ:GERN) by 6.5% during the third quarter, Holdings Channel.com reports. The fund owned 42,421 shares of the biopharmaceutical company’s stock after selling 2,925 shares during the period. Dynamic Technology Lab Private Ltd’s holdings in Geron were worth $193,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. National Bank of Canada FI grew its stake in Geron by 1,200.0% in the 2nd quarter. National Bank of Canada FI now owns 6,500 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 6,000 shares during the period. Rovin Capital UT ADV purchased a new position in Geron during the third quarter valued at $62,000. CIBC Asset Management Inc grew its position in shares of Geron by 32.7% in the second quarter. CIBC Asset Management Inc now owns 15,438 shares of the biopharmaceutical company’s stock valued at $65,000 after purchasing an additional 3,805 shares during the period. Csenge Advisory Group purchased a new stake in shares of Geron during the second quarter worth about $66,000. Finally, Empowered Funds LLC acquired a new position in shares of Geron during the 3rd quarter worth about $67,000. Hedge funds and other institutional investors own 73.71% of the company’s stock.

Geron Stock Down 1.9 %

Shares of NASDAQ GERN opened at $4.04 on Tuesday. Geron Co. has a 1 year low of $1.64 and a 1 year high of $5.34. The company has a market capitalization of $2.44 billion, a P/E ratio of -12.59 and a beta of 0.52. The company has a 50 day simple moving average of $4.16 and a 200-day simple moving average of $4.33. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.89 and a quick ratio of 2.74.

Geron (NASDAQ:GERN) last posted its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.05. The company had revenue of $28.27 million for the quarter, compared to the consensus estimate of $18.97 million. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The company’s revenue for the quarter was up 17138.4% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.08) earnings per share. On average, equities research analysts predict that Geron Co. will post -0.25 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on GERN. Leerink Partners assumed coverage on Geron in a report on Monday, September 9th. They issued an “outperform” rating and a $7.00 price objective on the stock. Scotiabank initiated coverage on Geron in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $6.00 price target for the company. StockNews.com raised Geron to a “sell” rating in a research note on Monday, August 5th. HC Wainwright assumed coverage on shares of Geron in a research note on Tuesday, November 5th. They set a “buy” rating and a $8.00 target price on the stock. Finally, Wedbush reiterated an “outperform” rating and issued a $8.00 target price on shares of Geron in a research report on Thursday, August 8th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $7.05.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.